Wadstrom H, et al. - Herein, the authors probed into the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs [bDMARDs]. Any significant variation was not found in the overall risk of cancer among patients with RA initiating tumor necrosis factor inhibitor (TNFi) as first or second bDMARD, tocilizumab, abatacept, or rituximab compared to the biologic drug–naive, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)-treated patients with RA. However, altered risks for specific cancer types, or those with longer latency, could not be excluded.